Fanvue | $22,000,000 | (Jan 20, 2026)
Dominion Dynamics | $15,200,000 | (Jan 20, 2026)
Tulip Interfaces | $120,000,000 | (Jan 20, 2026)
Certified by Founder
Lodge
Ratio Therapeutics
start up
United States
- Boston, MA
- 02/12/2021
- Unknown
- $1,500,000
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer.
Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.
- Industry Pharmaceutical Manufacturing
- Website https://ratiotx.com/
- LinkedIn https://www.linkedin.com/company/rat
Fleetzero | $43,000,000 | (Jan 20, 2026)
EXCIVA GmbH | $59,817,135 | (Jan 20, 2026)
Transition Metal Solutions | $6,000,000 | (Jan 20, 2026)
one • fıve | $16,320,500 | (Jan 20, 2026)
Anzen Industries | $2,283,975 | (Jan 20, 2026)
Gutology | $2,418,300 | (Jan 20, 2026)
GovDash | $30,000,000 | (Jan 16, 2026)
RouteSense | $2,000,000 | (Jan 16, 2026)
Vista AI | $29,500,000 | (Jan 16, 2026)